Frontiers in Pharmacology (Aug 2021)

Interleukin-6: A Novel Target for Cardio-Cerebrovascular Diseases

  • Jian-Hui Su,
  • Jian-Hui Su,
  • Meng-Yi Luo,
  • Meng-Yi Luo,
  • Na- Liang,
  • Shao-Xin Gong,
  • Wei Chen,
  • Wei Chen,
  • Wen-Qian Huang,
  • Wen-Qian Huang,
  • Ying Tian,
  • Ai-Ping Wang,
  • Ai-Ping Wang

DOI
https://doi.org/10.3389/fphar.2021.745061
Journal volume & issue
Vol. 12

Abstract

Read online

Cardio-Cerebrovascular Disease is a collective term for cardiovascular disease and cerebrovascular disease, being a serious threat to human health. A growing number of studies have proved that the content of inflammatory factors or mediators determines the stability of vascular plaque and the incidence of cardio-cerebrovascular event, and involves in the process of Cardio-Cerebrovascular Diseases. Interleukin-6 is a widely used cytokine that causes inflammation and oxidative stress, which would further result in cardiac and cerebral injury. The increased expression of interleukin-6 is closely related to atherosclerosis, myocardial infarction, heart failure and ischemic stroke. It is a key risk factor for these diseases by triggering inflammatory reaction and inducing other molecules release. Therefore, interleukin-6 may become a potential target for Cardio-Cerebrovascular Diseases in the future. This paper is aimed to discuss the expression changes and pathological mechanisms of interleukin-6 in Cardio-Cerebrovascular Diseases, and to provide a novel strategy for the prevention and treatment of Cardio-Cerebrovascular Diseases.

Keywords